Market Reaction
Abivax, the French biotechnology company, saw its shares climb approximately 27% in early European trading on 30 June 2026 after publishing new clinical data on its experimental ulcerative colitis therapy, obefazimod.
Drug Mechanism
Obefazimod is an oral agent that elevates levels of microRNA miR‑124, which modulates the body’s inflammatory response.
Trial Results – Hard‑to‑Treat Cohort
The latest analysis focused on patients who had not responded to an initial induction course of obefazimod. After continued treatment at a 50 mg dose, 37.2% of these patients achieved clinical remission by week 44, and 34.5% reached endoscopic remission.
Relapse Sub‑Group Findings
Among patients who relapsed during the early maintenance phase, increasing the dose to 50 mg restored clinical remission in 45.5% of cases.
Earlier June 1 Data from Same Trial
Data released on 1 June 2026 indicated that 50.8% of patients receiving a 25 mg dose and 51.3% on a 50 mg dose achieved clinical remission, compared with 10.4% of patients on placebo.
Regulatory Outlook
Abivax confirmed its intention to file a new drug application (NDA) for obefazimod with the U.S. Food and Drug Administration in the fourth quarter of 2026.
Implications
The combination of robust remission rates in difficult‑to‑treat patients and a clear regulatory filing timeline underpins the market’s positive reaction, reflected in the 27% share price increase.